Fadogia agrestis to Improve Testosterone

Evidence Review created on 09/14/2026 using AI4L / Opus 5

Also known as: Vangueria agrestis, Black Aphrodisiac, Bakin Gagai

Motivation

Fadogia agrestis (also catalogued as Vangueria agrestis) is a small shrub of the West African savanna, where boiled preparations of the stem and root have long been used for fever, pain and sexual complaints. In the past few years its dried stem extract has moved from that regional context into capsules sold worldwide as a natural way to raise testosterone. The claim is simple: the plant prompts the testes to make more of the hormone.

The evidence has an unusual shape. Everything known about the plant’s effect on testosterone comes from a handful of experiments in rats run by one Nigerian laboratory, which also reported signs of strain in the liver, kidneys and testes of those animals. No person has been studied in a published trial. Commercial demand has meanwhile grown fast enough that bark is exported by the ton, and analyses of retail products have found wide variation in what the capsules contain.

This review examines what the animal work shows and does not show, how the proposed mechanism is meant to operate, what the reported organ effects amount to, how products are dosed and sourced, and which measurements would reveal benefit or harm.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Vangueria agrestis

Grokipedia files the plant under its accepted name and covers taxonomy, West African ethnobotany, phytochemistry and the rodent testosterone work, including the European novel-food consultation and the overharvesting pressure in northern Nigeria.

Examine

Fadogia agrestis benefits, dosage, and side effects

Examine’s dedicated page states flatly that no human study exists, declines to recommend any dosage on that basis, and summarises the rodent testosterone magnitudes, the product-quality findings and the pregnancy and lactation position.

ConsumerLab

No ConsumerLab article on Fadogia agrestis exists. The site has never published a product review or any dedicated page for this plant; it is named only in passing inside two broader articles, a testosterone-booster answer and a sexual-enhancer product review, neither of which is a page about this plant.

Systematic Reviews

No systematic reviews or meta-analyses for Fadogia agrestis were found on PubMed as of 14 September 2026.

Neither side of the trade-off is represented in the systematic-review literature: there is no systematic review or meta-analysis of the claimed testosterone benefit, and none of the principal risk, the hepatic, renal and testicular effects reported in rodents.

Mechanism of Action

The proposed mechanism begins in the testis. Aqueous stem extract given to male rats raised serum testosterone dose-dependently, and the same laboratory found higher testicular cholesterol, the raw material from which testosterone is built, in treated animals, consistent with increased delivery of substrate to the steroid-producing Leydig cells.

Two competing readings of that finding exist. The upstream reading, widely repeated in supplement marketing, holds that saponins and alkaloids in the stem act on the pituitary to release luteinizing hormone (LH, the pituitary signal that tells the testes to make testosterone), which then drives Leydig-cell output. The downstream reading holds that the extract acts directly on the testis, mobilising cholesterol without any pituitary step. The published rodent work does not separate them: the aphrodisiac study measured testosterone alone, and no study has measured LH and testosterone in the same treated animals under conditions that would distinguish a pituitary effect from a gonadal one.

A third reading treats the hormone rise as a stress artefact: the same doses that raised testosterone also shifted testicular enzyme activity and disturbed hepatic and renal enzyme activity, and a damaged testis can leak steroid rather than secrete more of it.

Pharmacological properties are essentially uncharacterised. No human pharmacokinetic study exists, the half-life of any constituent is unknown, tissue distribution has not been mapped, and no metabolising enzyme, cytochrome P450 or otherwise, has been identified.

Historical Context & Evolution

The plant’s documented use is West African and domestic rather than pharmaceutical. Hausa communities in northern Nigeria prepare stem and root decoctions under the name bakin gagai for fever, pain, malaria, diarrhoea and urinary complaints, and the same material carries a long-standing local reputation as an aphrodisiac. An ethnobotanical survey in Burkina Faso recorded it among plants selected by traditional practitioners against malaria, and laboratory testing of those collections showed measurable activity against chloroquine-resistant Plasmodium falciparum, the parasite that causes the most severe form of malaria.

The shift toward hormone optimisation dates to 2005, when a group at the University of Ilorin tested the aqueous stem extract for aphrodisiac activity in male rats and reported a dose-dependent rise in serum testosterone alongside changes in mating behaviour. Those findings were published in a specialist andrology journal and attracted little attention for over a decade.

Two later papers from the same group qualified the picture: a 28-day study described the extract’s effect on testicular function indices as adverse, and a companion toxicology study described disrupted membrane integrity in liver and kidney. These are not refutations of the 2005 result, the testosterone rise was not retracted or contradicted, but they place it beside an organ-level cost observed at the same doses.

Interest broadened sharply from 2022, when podcast coverage of male hormone optimisation brought the plant to a mass audience and retail supply expanded to match.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: every reported outcome is rodent data, behavioural mating counts and serum hormone assays in albino and Wistar rats, and no human clinical endpoint or validated human surrogate has been measured in a single trial.

Medium 🟩 🟩

No benefit reaches Medium either: there is no single human trial and no observational human cohort of any size, so the only human-level material in existence is uncontrolled consumer self-report.

Low 🟩

Speculative 🟨

Elevated Serum Testosterone

Aqueous stem extract raised serum testosterone dose-dependently in male rats across 18, 50 and 100 mg/kg over five days. The basis is one rodent experiment; no human measurement exists.

Increased Sexual Motivation and Performance

Treated rats mounted and intromitted more often, with shorter latencies and prolonged ejaculatory latency, at every dose from day one. The basis is rodent mating behaviour; no human sexual-function trial exists.

Restored Erectile Signalling Chemistry

In rats with drug-induced erectile failure, extract raised penile nitric oxide and cyclic GMP (the messenger relaxing penile vessels) toward sildenafil-like values. The basis is one animal model.

Increased Relative Testicular Weight ⚠️ Conflicted ⭕️ Not Central to Improve Testosterone

Testes-to-body-weight ratio rose at all rodent doses; it bears on testicular mass, not circulating androgen. Marketing reads growth, the investigators read organ stress. Net: an unexplained rodent finding, not a demonstrated benefit.

Antiplasmodial and Anti-Infective Activity ⭕️ Not Central to Improve Testosterone

Crude extracts inhibited chloroquine-resistant malaria parasites in culture, and isolated root glycosides inhibited Trypanosoma brucei (the sleeping-sickness parasite). This bears on infection, not androgen status, and the basis is laboratory assays only.

Analgesic and Anti-Inflammatory Activity ⭕️ Not Central to Improve Testosterone

Stem-bark extract matched aspirin’s potency in rodent pain and swelling models at 200 mg/kg. This bears on pain and inflammation, not androgen status; the basis is animal work only.

Benefit-Modifying Factors

Genetic polymorphisms: No pharmacogenetic study exists. Variants in CYP19A1 (the gene for aromatase, which converts testosterone to estrogen) and SRD5A2 (the gene for 5-alpha-reductase, which converts testosterone to its more potent form) would plausibly shift where any added androgen ends up.
Baseline testosterone: Men beginning in the lower part of the reference range have the most headroom; those already near the top have little to gain while carrying identical organ exposure. No trial has stratified by baseline, so this is inference from androgen physiology.
Sex: Every published experiment used male animals. Nothing is known about effects in women, and the only stated position, Examine’s, is avoidance during pregnancy and lactation for want of safety evidence.
Pre-existing conditions: Untreated obstructive sleep apnea (repeated breathing pauses during sleep), obesity and poorly controlled diabetes each suppress testosterone through mechanisms this extract does not touch, so any effect is likely to be swamped where those remain unaddressed.
Age: Testicular reserve falls with age, so the Leydig cells an upstream signal would act on are fewer and less responsive after sixty-five. The rodent work used young adult animals exclusively; nothing addresses older physiology.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: there is no documented human adverse-event series, no pharmacovigilance signal specific to this plant, and no controlled human safety study of any duration.

Medium 🟥 🟥

No risk reaches Medium either: not one human trial or observational cohort has recorded any safety outcome, so every severity estimate rests on rodent organ chemistry.

Low 🟥

Speculative 🟨

Hepatocellular and Renal Membrane Injury ⚠️ Conflicted

Across 28 days at all doses, rat liver and kidney enzymes fell in tissue, rose in serum with raised oxidation by-products, yet no organ swelling, symptoms or deaths occurred. Net: biochemical strain without overt injury.

Impaired Testicular Function

Across 28 days at all doses, rat testicular enzyme activity and protein content shifted in directions the investigators called adverse; recovery after ten days off occurred only at the lowest dose. Rodent biochemistry only.

Unlabelled and Variable Active Content

Chromatography of seventeen retail products found marker phenolics absent from five and ranging 0.3–2.7 mg daily in the rest, so dose and even identity are unverifiable from the label. Analytical, not clinical, evidence.

Cardiotoxicity from Genus-Level Misidentification

Sister species Fadogia homblei produces pavettamine, which causes fatal heart-muscle degeneration in grazing ruminants. Wild-harvested, unverified material could carry it; no human case is documented.

Estrogenic Overshoot

A sustained testosterone rise is partly converted to estradiol by aromatase, risking breast tenderness and fluid retention. No study has measured estradiol under this extract; the concern is mechanistic.

Erythrocytosis (Thickened Blood)

Androgen elevation drives red-cell production, raising haematocrit (the share of blood volume made of red cells) and, above roughly 52%, thrombotic risk. Extrapolated from androgen physiology; never measured under this extract.

Risk-Modifying Factors

Genetic polymorphisms: No pharmacogenetic data exist for this plant. Slow-metabolizer variants of CYP3A4 (the liver enzyme clearing most oral compounds) would plausibly raise exposure, but no constituent has been assigned to any enzyme.
Baseline biomarkers: Liver enzymes already above the reference range, or an estimated kidney filtration rate below 60, place a person on the steep part of the curve for the organ effects rodents showed at every dose tested.
Sex: All toxicology was done in male rats. Whether the hepatic and renal membrane effects differ in women is entirely unstudied, and no product carries female dosing or safety information.
Pre-existing conditions: Fatty liver disease, hepatitis, chronic kidney disease and prostate cancer each convert a theoretical organ signal into a live concern; a history of blood clots does the same for any androgen-driven rise in red-cell mass.
Age: Hepatic blood flow and kidney filtration both decline with age, so an identical capsule delivers a larger effective exposure after sixty-five, the age band this product is most heavily marketed to.

Key Interactions & Contraindications

Hepatotoxic prescription medications (methotrexate, isoniazid, amiodarone, valproate, ketoconazole): caution, additive hepatocellular injury on the target the rodent data implicate. Mitigation: avoid concurrent use; where unavoidable, liver enzymes before starting and at four weeks.
Androgen therapies (testosterone cypionate, testosterone gel, enclomiphene, human chorionic gonadotropin): caution, additive androgen load with unpredictable estradiol and red-cell response, and effects can no longer be attributed. Mitigation: separate by at least one full cycle.
Over-the-counter analgesics (acetaminophen, ibuprofen, naproxen, diclofenac): caution, acetaminophen adds hepatocellular burden, the others add renal tubular stress, both organs implicated in rodent dosing. Mitigation: keep acetaminophen below 2 g daily and limit continuous anti-inflammatory use.
Other androgenic botanicals (Eurycoma longifolia, Withania somnifera, Trigonella foenum-graecum, Lepidium meyenii): caution, additive androgen load with untested estradiol overshoot, producing breast tenderness and fluid retention, and no laboratory change attributable to one agent. Mitigation: introduce one agent at a time.
Liver-burdening supplements (concentrated green tea catechin extract, kava, Garcinia cambogia, high-dose niacin, prohormones): caution, additive hepatocellular injury, the best-documented supplement-related liver risk. Mitigation: do not run concurrently; stagger by at least four weeks.
Estrogen-lowering agents (anastrozole, exemestane, diindolylmethane, calcium-D-glucarate): caution, over-suppression of estradiol causes joint pain, low libido and bone loss, the opposite of the intended outcome. Mitigation: measure estradiol before adding any blocker.
Alcohol: caution, ethanol and the extract act on the same hepatocyte membranes, and alcohol independently lowers testosterone. Mitigation: abstain during a cycle, or keep intake under seven drinks weekly and confirm liver enzymes at four weeks.
Erectile-dysfunction medications (sildenafil, tadalafil, vardenafil): monitor, rodent work places the extract on the same nitric-oxide pathway these drugs extend, so a theoretical additive effect on blood pressure exists. Mitigation: start either agent alone.

Populations who should avoid Fadogia agrestis:

Anyone with active liver disease, or a baseline alanine aminotransferase or aspartate aminotransferase (ALT and AST, liver enzymes released when liver cells are injured) above 1.5 times the upper reference limit
Anyone with chronic kidney disease at an estimated glomerular filtration rate (eGFR, a calculated measure of kidney filtering capacity) below 60 mL/min/1.73 m²
Men with a history of prostate cancer, or a prostate-specific antigen (PSA, a prostate protein measured in blood) above 4 ng/mL
Men with a haematocrit above 52%
Men actively pursuing conception, given the rodent testicular findings
Women who are pregnant or lactating
Anyone under 18
Anyone taking a medication that carries a documented hepatotoxicity warning

Risk Mitigation Strategies

Baseline and on-cycle liver panel: ALT and AST measured before the first dose, at week four and at cycle end, to detect the hepatocellular strain rodents showed at every dose; stop at any rise beyond three times the upper limit.
Baseline and on-cycle kidney panel: creatinine with eGFR on the same schedule, addressing the renal membrane disruption reported across 28 days of rodent dosing; a fall of more than 15% warrants stopping.
Dose at the low end of the retail range: 200–300 mg daily rather than 600 mg keeps exposure nearer the only rodent dose from which organ indices recovered, reducing hepatic, renal and testicular strain.
Fixed cycling with washout: eight weeks on followed by four weeks off caps continuous exposure, mirroring the ten-day rodent withdrawal period in which some testicular indices recovered, and limits cumulative organ load.
Single-agent introduction: running the extract alone for one cycle before adding any other botanical makes an abnormal liver enzyme or estradiol value attributable, preventing the misattribution that stacking guarantees.
Certificate-of-analysis sourcing: buying only batches with a published chromatographic identity test and heavy-metal screen addresses the content variability found in seventeen retail products and the risk of wrong-species material.
Haematocrit check each cycle: a complete blood count at cycle end catches androgen-driven red-cell rise before it reaches the 52% threshold at which clot risk climbs.
Alcohol restriction during cycles: abstaining, or staying under seven drinks weekly, removes the most common additive insult to the hepatocyte membranes the rodent toxicology implicated.

Therapeutic Protocol

Standard dose: 300–600 mg daily of a 10:1 dried stem or root extract, the range sold at retail and the range a European novel-food dossier describes as the intended daily intake of 200–1000 mg.
Conservative dose anchored to the animal data: the lowest rodent dose that raised testosterone, 18 mg/kg, scales by body-surface conversion to roughly 200 mg for a 70 kg adult.
Competing approaches: the stack approach popularised on the Huberman Lab podcast with Kyle Gillett pairs 600 mg with tongkat ali; integrative clinicians favour 200–300 mg alone with tighter laboratory follow-up.
Time of day: morning dosing is standard, matching the natural early-morning peak in testosterone and keeping the blood draw and the dose on the same clock. No human data on dose timing exist.
Half-life: unknown. No constituent has been measured in human plasma, so the 24-hour interval used throughout the rodent work is the only empirical basis for once-daily dosing.
Single versus split dosing: every rodent experiment used one dose every 24 hours and retail products follow that pattern. No study has compared split dosing, so the single morning dose rests on convention.
Genetic polymorphisms: no pharmacogenetic guidance exists. Where CYP19A1 or SRD5A2 variants are already known, they predict where added androgen is routed rather than how much the extract produces.
Sex-based differences: no female protocol exists at any dose. Every published experiment used male animals, and the only stated guidance for women is avoidance in pregnancy and lactation.
Age-related adjustment: above sixty-five, reduced liver blood flow and kidney filtration make the same capsule a larger exposure, so protocols in this band start at 200 mg and shorten cycles to six weeks.
Baseline biomarkers: protocols are set after a morning hormone panel; starting below roughly 400 ng/dL of total testosterone leaves room to observe change, while an upper-range result leaves none.
Pre-existing conditions: fatty liver disease, chronic kidney disease and untreated sleep apnea each change the arithmetic, the first two raising organ exposure, the third suppressing testosterone through a route the extract does not address.

Discontinuation & Cycling

Not a lifelong intervention: no source describes continuous use. The absence of any human safety study, beyond a few weeks of rodent dosing, makes indefinite use unsupported, and every published protocol is bounded.
Cycling is the norm: eight weeks on with two to four weeks off, or twelve weeks on with four off, are the patterns described on the Huberman Lab podcast and repeated across retail labels.
No withdrawal syndrome documented: nothing resembling a withdrawal reaction has been reported in animals or in humans. Any benefit that depended on the extract would simply fade as the compound clears.
Tapering is not applicable: with no dependence signal and no receptor occupancy to unwind, protocols stop abruptly at cycle end rather than stepping the dose down.
Rodent recovery is partial: after ten days without dosing, several testicular indices returned toward control only at the lowest dose, and the raised testes-to-body-weight ratio did not return at all.
Stopping triggers: liver enzymes beyond three times the upper limit, a filtration fall over 15%, haematocrit above 52%, or new right-upper-abdominal pain each end a cycle immediately rather than at its scheduled close.

Sourcing and Quality

Species identity is the first check: labels should name Fadogia agrestis or its accepted synonym Vangueria agrestis. The genus contains species producing a cardiotoxin lethal to livestock, so botanical verification by chromatography matters more here than for common botanicals.
Plant part and extract ratio: the rodent testosterone data used an aqueous stem extract; retail capsules are usually 10:1 concentrates of stem, root or aerial parts. These are not interchangeable and the label should state which.
Third-party testing: a batch certificate of analysis showing chromatographic identity, heavy metals, pesticide residues and microbial counts is the minimum, given that marker compounds were undetectable in roughly a third of products analysed in one survey.
Brands and supply: products from suppliers that publish batch chromatograms, Nootropics Depot and Double Wood Supplements being commonly cited examples, carry more information than the private-label capsules that dominate marketplace listings.
Wild harvest and sustainability: bark is exported by the ton from West African herbal markets and the species is recorded as locally threatened by overharvesting in northern Nigeria, so supply is uncultivated and traceability is weak.
Adulteration with synthetic androgens: testosterone-marketed supplements frequently carry ingredients unsupported by their label claims. A product certified by a sport anti-doping testing programme removes most of that exposure.

Practical Considerations

Time to effect: rodent testosterone rose within one to five days, but no human timeline exists. Protocols assume an eight-week cycle before a follow-up hormone panel is meaningful, which is the earliest point any judgement can be made.
Common pitfalls: starting without a baseline hormone and liver panel, stacking with tongkat ali from day one, extrapolating the rodent milligram-per-kilogram dose directly to a human body weight, and treating an eight-week cycle as permanent.
Regulatory status: in the United States it is sold as a dietary supplement under the Dietary Supplement Health and Education Act, meaning no pre-market approval by the Food and Drug Administration. It is not on the World Anti-Doping Agency prohibited list.
European status: a 10:1 extract of the plant is under novel-food consultation in the European Union, which means it is not yet authorised for sale as a food supplement across the bloc.
Cost and accessibility: capsules are inexpensive and widely available online, typically under twenty United States dollars monthly. Cost is not a barrier; verified identity and batch testing are the scarce commodities.

Interaction with Foundational Habits

Sleep: Direction unknown and untested, since no human study has measured sleep with this extract. Any androgen rise would indirectly favour sleep-dependent recovery, while untreated sleep apnea both lowers testosterone and worsens with rising haematocrit. Practically: fix sleep before adding a botanical, and dose in the morning.
Nutrition: Indirect and potentiating. Testosterone synthesis draws on cholesterol, so very low-fat intakes below roughly 20% of calories blunt any hormonal effect; zinc and vitamin D deficiency do the same. The extract is given with water in rodent work and with food in retail practice; no absorption data exist.
Exercise: Indirect. Resistance training raises testosterone acutely and is the better-evidenced lever; no study has tested whether the extract adds to it or blunts adaptation. Because heavy training and this extract both raise serum liver enzymes transiently, blood should be drawn at least 48 hours after a hard session.
Stress management: Indirect and blunting in the opposite direction. Chronic cortisol elevation suppresses the pituitary signal the plant is proposed to raise, so an unmanaged stress load can cancel the mechanism before it operates. No study has measured cortisol under this extract in any species.

Monitoring Protocol & Defining Success

Because no human trial has established either efficacy or safety, monitoring here serves two purposes: to detect whether the extract changes androgen status in the individual at all, and to catch the organ effects seen in rodents before they become symptomatic. Baseline testing is drawn fasting and in the early morning, before the first capsule: total and free testosterone, luteinizing hormone, follicle-stimulating hormone (FSH, the pituitary signal driving sperm production), sex hormone-binding globulin (SHBG, the carrier protein holding most testosterone in the blood), estradiol, a complete blood count, a liver panel and a kidney panel. Ongoing testing repeats the same panel at week 4 and at the end of each cycle, then at every subsequent cycle end; anyone continuing beyond three cycles repeats it every three to six months. Hormones are always redrawn at the same hour to keep results comparable.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Total testosterone	600–900 ng/dL	The outcome the intervention targets	Draw 07:00–10:00 fasting; conventional labs call 264–916 ng/dL normal, functional practice targets the upper half
Free testosterone	15–25 ng/dL	The fraction actually available to tissues; moves independently of total	Equilibrium dialysis preferred over calculation; interpret alongside SHBG
Luteinizing hormone (LH)	4–8 IU/L	Separates a pituitary-driven rise from a direct testicular one	Same draw as testosterone; a rise moving with testosterone supports the upstream mechanism
Follicle-stimulating hormone (FSH)	1.5–8 IU/L	Reads the other half of the pituitary–testis loop; falls if the axis is suppressed	Paired with LH in the same draw
Sex hormone-binding globulin (SHBG)	20–45 nmol/L	Determines how much measured testosterone is free	Rises with age, thyroid excess and low insulin; conventional range runs to 60 nmol/L
Estradiol, sensitive assay	20–30 pg/mL	Testosterone converts to estradiol; overshoot causes breast tenderness and fluid retention	Liquid chromatography–mass spectrometry (a laboratory separation-plus-identification method) only; standard immunoassay overestimates in men
Alanine and aspartate aminotransferase (ALT, AST)	ALT 10–26 U/L; AST 10–26 U/L	Detects the hepatocellular strain reported at every rodent dose	Conventional upper limits of 40–55 U/L are far looser; avoid intense exercise for 48 hours before the draw
Gamma-glutamyl transferase (GGT)	<20 U/L	Bile-duct and oxidative-stress-sensitive liver enzyme; shifted in rodent dosing	Conventional range extends to 60 U/L; alcohol raises it independently of any supplement
Creatinine with eGFR	eGFR >90 mL/min/1.73 m²	Detects the renal membrane effect reported in rodents	Creatinine rises with muscle mass and creatine use; cystatin C is a useful cross-check
Haematocrit	40–48%	Androgen elevation thickens blood	Part of the complete blood count; above 52% is the conventional trigger to stop any androgen
Prostate-specific antigen (PSA)	<1.5 ng/mL under age 60	Baseline safety anchor for anyone raising androgens	Not a plant-specific effect; avoid ejaculation and cycling for 48 hours before the draw
Serum malondialdehyde (MDA)	No established target; track change from the individual’s own baseline instead	The oxidative-damage marker that rose in every rodent treatment group	A research assay rather than a routine clinical one; most laboratories do not offer it

Qualitative markers tracked alongside the panel:

Libido and frequency of spontaneous morning erections
Morning energy and training drive
Mood stability and irritability
Sleep quality and number of night wakings
Early liver warning signs: right-upper-abdominal discomfort, dark urine, unusual fatigue, yellowing of the eyes

Emerging Research

No registered trial of the plant exists: a ClinicalTrials.gov search returned zero studies naming Fadogia agrestis or Vangueria agrestis as of 14 September 2026. Every claim in circulation therefore rests on preclinical work, and a first registered human study would be the single largest change to this picture.
Adjacent registered work on the co-marketed agent: NCT05347329, a completed 197-participant trial of a tongkat ali and maca combination in erectile dysfunction, and NCT06100432, an active phase 4 study of Eurycoma longifolia in 90 infertile men, test the category this plant is sold within.
Chemistry that would make a trial possible: Osman et al., 2021 characterised three previously undescribed monoterpene rhamnosides, and Avula et al., 2019 built a quantification method. Neither is yet tied to the testosterone effect, and no trial can be designed until a marker is chosen.
The erectile-signalling line of work: Ogunro & Yakubu, 2023 reported restored nitric-oxide signalling in drug-impaired rats and closed by calling for clinical trials. A positive human replication would move this item from speculative to graded evidence.
Evidence that could weaken the case: Morgado et al., 2024 reviewed 52 studies of 27 testosterone boosters and found most fail to raise the hormone, and Sharma et al., 2026 urges active surveillance for liver injury across this whole class.
Regulatory evaluation as a source of new safety data: the European novel-food consultation on a 10:1 extract, filed through the Czech Republic, would require a toxicological dossier of a kind that does not currently exist in the published literature.

Conclusion

Fadogia agrestis is a West African shrub whose stem extract is sold as a natural means of raising testosterone. The case for it rests entirely on animal work: in rats it raised the hormone in step with the dose and changed mating behaviour, and a later animal study found the signalling chemistry of erection moving in a favourable direction. No person has been studied in a published trial, so none of it has been shown to carry across to people.

The same rodent experiments that produced the hormone finding also produced the main safety concern. At every dose tested, markers of liver, kidney and testicular function shifted in ways the investigators read as cellular strain, with only partial recovery at the lowest dose after dosing stopped. Whether that matters at the amounts in capsules is unknown.

A second layer of uncertainty sits in the product itself. Chemical analysis of retail supplements has found the marker compounds present in widely differing amounts and absent altogether from a substantial minority, so two identically labelled capsules need not contain the same material. The plant is wild-harvested and shares a genus with species that are lethally toxic to grazing animals.

The evidence base is small, produced almost entirely by one academic laboratory with no commercial stake, and unaccompanied by any human safety data; the claims that carry it to buyers come from the firms selling the capsules. On that basis the benefit remains a hypothesis and the questions about organ strain remain open.

Top - Benefits - Risks - Protocol

Fadogia agrestis to Improve Testosterone

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Low 🟩

Speculative 🟨

Elevated Serum Testosterone

Increased Sexual Motivation and Performance

Restored Erectile Signalling Chemistry

Increased Relative Testicular Weight ⚠️ Conflicted ⭕️ Not Central to Improve Testosterone

Antiplasmodial and Anti-Infective Activity ⭕️ Not Central to Improve Testosterone

Analgesic and Anti-Inflammatory Activity ⭕️ Not Central to Improve Testosterone

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Low 🟥

Speculative 🟨

Hepatocellular and Renal Membrane Injury ⚠️ Conflicted

Impaired Testicular Function

Unlabelled and Variable Active Content

Cardiotoxicity from Genus-Level Misidentification

Estrogenic Overshoot

Erythrocytosis (Thickened Blood)

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion